Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Exclusive: Sweden’s Lobsor Gains U.S. Patent for Advanced Parkinson’s Disease Treatment

Privately held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.

Read More »

Celgene, Exscientia Ink Three-Year AI Research Deal

U.K.-based Exscientia signed a three-year artificial intelligence (AI)-based drug discovery collaboration with Celgene.

Read More »

Gottlieb Reflects on His Time as FDA Commissioner, Approval of Dsuvio During the Opioid Crisis

As Scott Gottlieb prepares to step down from his role as commissioner of the U.S. Food and Drug Administration, he sat down with Politico to talk about his two years at the helm of the regulatory agency and what regrets he may be leaving behind.

Read More »

More Ovarian Cancer Woes for Merck KGaA and Pfizer as They Halt Late-Stage Trial

Merck KGaA of Darmstadt, Germany and Pfizer Inc. discontinued a Phase III ovarian cancer drug trial after determining that the degree of benefit observed in the treatment during an interim analysis does not support the continuation of the study.

Read More »

Seven Projected Blockbuster Drugs by 2023

A market research report by Clarivate Analytics named “Cortellis Drugs to Watch” identified seven new drugs the company believes will hit sales of $1 billion or more – the so-called “blockbuster” mark – by 2023.

Read More »

Sage Wins FDA Approval for ‘Game-Changing’ Postpartum Depression Treatment

Sage Therapeutics shares were up after the company won approval for the postpartum depression treatment Zulresso (brexanalone).

Read More »

Vivek Ramaswamy’s Urovant Headed to FDA With Vibegron After Positive Phase III Data

Urovant Sciences announced positive top-line results from the company’s Phase III EMPOWUR trial of vibregron in patients with overactive bladder.

Read More »

Starboard, Opposed to BMS Deal for Celgene, Readies for Fight at April Meeting

One of the groups of shareholders opposing the Bristol-Myers Squibb acquisition of Celgene is ready for a fight at the April 12, 2019, shareholder meeting.

Read More »

Women’s History Month: Top Influential Women in Biopharma

March is National Women’s Month, and BioSpace recognized these 10 women as being especially influential in the biopharma industry.

Read More »

Alcon Acquires PowerVision for $285 Million

Alcon, the eye care division of Novartis, acquired fluid-based intraocular lens maker PowerVision Inc. for $285 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom